                                                    Concept  PeriodEnd                                                                                                                                                              Dims        Value
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                          srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 7.142000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 1.216000e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                          srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 1.861900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 1.851000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 2.244000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 2.618000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 8.993000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 1.440400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:HUMIRAMember 2.123700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                         srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 1.008600e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                         srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 6.753000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                         srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 4.484000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 1.632000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 1.010000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 6.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 1.171800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 7.763000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                   abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:SKYRIZIMember 5.165000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                          srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 4.259000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                          srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 2.824000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                          srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 1.794000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 1.712000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 1.145000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                 srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 7.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 5.971000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 3.969000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                    abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember; srt:ProductOrServiceAxis:abbv:RINVOQMember 2.522000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember 2.448000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember 2.665000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember 3.426000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember 3.347000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember 3.596000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:ImbruvicaMember 4.568000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 1.234000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 1.087000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 1.009000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31     srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 1.349000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31     srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 1.201000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31     srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 1.000000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 2.583000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 2.288000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:VENCLEXTAMember 2.009000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:ElahereMember 4.770000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31       srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:ElahereMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                          abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:ElahereMember 4.790000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31       srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember 2.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31       srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                          abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember 1.460000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                          abbv:KeyProductPortfolioAxis:abbv:HematologicOncologyMember; srt:ProductOrServiceAxis:abbv:EpkinlyMember 3.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                   srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 1.682000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 1.670000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                   srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 1.654000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 1.038000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 1.012000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 9.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 2.720000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 2.682000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember 2.615000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 4.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 5.190000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 5.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31     srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 7.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31     srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 8.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31     srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 8.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 1.177000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 1.378000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember 1.428000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                 srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.118000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                 srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.060000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                 srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.122000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31        srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31        srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31        srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                           abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.279000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                           abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.234000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                           abbv:KeyProductPortfolioAxis:abbv:AestheticsMember; srt:ProductOrServiceAxis:abbv:OtherAestheticsMember 1.290000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 2.718000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 2.476000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31              srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 2.255000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31     srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 5.650000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31     srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 5.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31     srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 4.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 3.283000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 2.991000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                        abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember 2.719000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 3.260000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 2.755000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 2.037000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 7.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 4.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 1.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 3.267000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 2.759000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:VraylarMember 2.038000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 9.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 9.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 9.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 3.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 3.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 3.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 4.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 4.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:DuodopaMember 4.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 9.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 8.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 6.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 2.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 1.006000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 8.150000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:UbrelvyMember 6.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 6.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 4.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 1.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 6.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 4.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:QuliptaMember 1.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31             srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 2.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31             srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 2.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31             srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 4.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31    srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 1.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31    srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 2.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31    srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 1.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 3.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 2.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                       abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember; srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember 4.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                            srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 1.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                            srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 1.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                            srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 1.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 3.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 3.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                   srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 2.890000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                      abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 4.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                      abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 4.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                      abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OzurdexMember 4.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                     srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 1.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                     srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 1.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                     srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 2.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31            srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 2.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31            srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 2.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31            srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 2.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                               abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 4.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                               abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 4.320000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                               abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:LumiganGanfortMember 5.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                   srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 9.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 1.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                   srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 2.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 1.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 1.510000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 1.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 2.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 2.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember 3.460000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                           srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:RestasisMember 1.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                           srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:RestasisMember 3.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                           srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:RestasisMember 6.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:RestasisMember 5.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:RestasisMember 5.400000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                  srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:RestasisMember 4.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                     abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:RestasisMember 2.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                     abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:RestasisMember 4.360000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                     abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:RestasisMember 6.660000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 4.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 4.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                       srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 3.990000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 3.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 3.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31              srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 3.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 8.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 8.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                 abbv:KeyProductPortfolioAxis:abbv:EyeCareMember; srt:ProductOrServiceAxis:abbv:OtherEyeCareMember 7.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                   srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 5.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                   srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 6.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                   srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 7.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 7.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 7.710000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31          srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 7.860000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 1.311000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 1.430000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                             abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:MAVYRETMember 1.541000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                     srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:CreonMember 1.383000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                     srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:CreonMember 1.268000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                     srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:CreonMember 1.278000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31          srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 9.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31          srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 1.073000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31          srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 1.003000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31 srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 3.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31 srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 3.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31 srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 3.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                    abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 9.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                    abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 1.108000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                    abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember; srt:ProductOrServiceAxis:abbv:LinzessConstellaMember 1.035000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 3.032000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 3.035000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 4.137000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:US 4.302900e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:US 4.188300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:US 4.571300e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:DE 1.465000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:DE 1.266000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:DE 1.340000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:JP 1.122000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:JP 1.008000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:JP 9.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CA 1.088000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CA 1.076000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CA 1.159000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CN 9.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CN 9.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:CN 9.120000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:FR 7.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:FR 7.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:FR 7.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:ES 5.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:ES 5.010000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:ES 5.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:GB 5.220000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:GB 4.170000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:GB 4.620000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:IT 5.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:IT 4.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:IT 4.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:BR 4.640000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:BR 4.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:BR 4.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                          srt:StatementGeographicalAxis:country:AU 4.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                          srt:StatementGeographicalAxis:country:AU 4.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                          srt:StatementGeographicalAxis:country:AU 5.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                           srt:StatementGeographicalAxis:abbv:OtherCountriesMember 5.449000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                           srt:StatementGeographicalAxis:abbv:OtherCountriesMember 5.042000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                           srt:StatementGeographicalAxis:abbv:OtherCountriesMember 4.837000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-12-31                                                                                                                                                                   5.633400e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2023-12-31                                                                                                                                                                   5.431800e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2022-12-31                                                                                                                                                                   5.805400e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                   5.633400e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                   5.431800e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                   5.805400e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                   5.633400e+10
                                           us-gaap:Revenues 2023-12-31                                                                                                                                                                   5.431800e+10
                                           us-gaap:Revenues 2022-12-31                                                                                                                                                                   5.805400e+10
                                           us-gaap:Revenues 2024-12-31                                                                                                                                                                   1.510200e+10
                                us-gaap:OperatingIncomeLoss 2024-12-31                                                                                                                                                                   9.137000e+09
                                us-gaap:OperatingIncomeLoss 2023-12-31                                                                                                                                                                   1.275700e+10
                                us-gaap:OperatingIncomeLoss 2022-12-31                                                                                                                                                                   1.811700e+10
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                         srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 3.843000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.340000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                         srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 6.762000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 3.996000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 5.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 3.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.086000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                srt:ProductOrServiceAxis:abbv:SKYRIZIMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 7.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                   srt:ProductOrServiceAxis:abbv:SKYRIZIMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.423000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:abbv:SKYRIZIMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.727000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                   srt:ProductOrServiceAxis:abbv:SKYRIZIMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 7.848000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:abbv:SKYRIZIMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.735000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                          srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.452000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.017000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                          srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.672000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.742000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                 srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 5.760000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                 srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.130000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                 srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.074000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                 srt:ProductOrServiceAxis:abbv:RINVOQMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 7.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                    srt:ProductOrServiceAxis:abbv:RINVOQMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.028000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                    srt:ProductOrServiceAxis:abbv:RINVOQMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.430000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                    srt:ProductOrServiceAxis:abbv:RINVOQMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 3.746000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                    srt:ProductOrServiceAxis:abbv:RINVOQMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.523000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 8.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.360000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.546000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.546000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.131000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                          srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.131000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 3.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 4.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 7.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 7.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 9.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                 srt:ProductOrServiceAxis:abbv:HUMIRAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 9.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 1.180000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.814000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.301000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 2.301000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 5.084000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                    srt:ProductOrServiceAxis:abbv:HUMIRAMember; abbv:KeyProductPortfolioAxis:abbv:ImmunologyMember 5.084000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.980000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.730000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.661000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.465000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:VraylarMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 3.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:VraylarMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:VraylarMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:VraylarMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.665000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:VraylarMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.468000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 6.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.498000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.280000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30     srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30     srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.450000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30     srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30     srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                        srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                        srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                        srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.794000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                        srt:ProductOrServiceAxis:abbv:BotoxTherapeuticMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.562000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 3.300000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.630000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:UbrelvyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:UbrelvyMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 3.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:UbrelvyMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.310000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:UbrelvyMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.780000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:UbrelvyMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.340000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.460000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.740000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:QuliptaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:QuliptaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                        srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                        srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30               srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30               srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30               srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30               srt:ProductOrServiceAxis:abbv:VyalevMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                  srt:ProductOrServiceAxis:abbv:VyalevMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                  srt:ProductOrServiceAxis:abbv:VyalevMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                  srt:ProductOrServiceAxis:abbv:VyalevMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                  srt:ProductOrServiceAxis:abbv:VyalevMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 7.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.530000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:DuodopaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:DuodopaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:DuodopaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.130000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:DuodopaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.930000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:DuodopaMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 2.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30             srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30             srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.700000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30             srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30             srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30    srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 4.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30    srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30    srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 8.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30    srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 9.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                       srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 5.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                       srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 6.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                       srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                       srt:ProductOrServiceAxis:abbv:OtherNeuroscienceMember; abbv:KeyProductPortfolioAxis:abbv:NeuroscienceMember 1.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                         srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 5.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 5.950000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                         srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.072000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:abbv:ImbruvicaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.205000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                   srt:ProductOrServiceAxis:abbv:ImbruvicaMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 7.540000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:abbv:ImbruvicaMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 8.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                   srt:ProductOrServiceAxis:abbv:ImbruvicaMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.492000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:abbv:ImbruvicaMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.671000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                         srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                         srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 6.330000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                         srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 5.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 7.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 6.700000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                   srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 6.910000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 6.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                   srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.356000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                   srt:ProductOrServiceAxis:abbv:VENCLEXTAMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.251000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                           srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                           srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                           srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                           srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                  srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                  srt:ProductOrServiceAxis:abbv:ElahereMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                     srt:ProductOrServiceAxis:abbv:ElahereMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                     srt:ProductOrServiceAxis:abbv:ElahereMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.280000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                     srt:ProductOrServiceAxis:abbv:ElahereMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                     srt:ProductOrServiceAxis:abbv:ElahereMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                  srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                  srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 7.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                  srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                  srt:ProductOrServiceAxis:abbv:EpkinlyMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                     srt:ProductOrServiceAxis:abbv:EpkinlyMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 7.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                     srt:ProductOrServiceAxis:abbv:EpkinlyMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                     srt:ProductOrServiceAxis:abbv:EpkinlyMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 1.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                     srt:ProductOrServiceAxis:abbv:EpkinlyMember; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 6.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                     srt:ProductOrServiceAxis:abbv:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                     srt:ProductOrServiceAxis:abbv:OtherOncologyMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OncologyMember 2.000000e+06
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                   srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 4.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 4.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                   srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 7.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 8.390000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30          srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.790000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30          srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 5.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 5.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                             srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 6.920000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                             srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 7.290000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                             srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.248000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                             srt:ProductOrServiceAxis:abbv:BotoxCosmeticMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.362000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.380000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.800000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30     srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 1.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30     srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.050000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30     srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30     srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.960000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                        srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.600000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                        srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.430000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                        srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 4.910000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                        srt:ProductOrServiceAxis:abbv:JuvedermCollectionMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 6.400000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                 srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.820000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                 srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 2.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                 srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 5.520000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                 srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 5.560000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30        srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 4.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30        srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 4.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30        srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 9.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30        srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 8.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                           srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.270000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                           srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 3.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                           srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 6.420000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                           srt:ProductOrServiceAxis:abbv:OtherAestheticsMember; abbv:KeyProductPortfolioAxis:abbv:AestheticsMember 6.370000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                            srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                            srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                            srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 6.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                            srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 6.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                   srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 9.500000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 8.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                   srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.880000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:abbv:OzurdexMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.860000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                      srt:ProductOrServiceAxis:abbv:OzurdexMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.250000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                      srt:ProductOrServiceAxis:abbv:OzurdexMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.240000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                      srt:ProductOrServiceAxis:abbv:OzurdexMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.480000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                      srt:ProductOrServiceAxis:abbv:OzurdexMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                     srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 5.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                     srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 4.200000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                     srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.000000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                     srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 7.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30            srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 5.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30            srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 6.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30            srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30            srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.230000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                               srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                               srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                               srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.090000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                               srt:ProductOrServiceAxis:abbv:LumiganGanfortMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.940000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.300000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                   srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.800000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30          srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30          srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 7.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 8.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                             srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 3.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                             srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 4.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                             srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 9.600000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                             srt:ProductOrServiceAxis:abbv:AlphaganCombiganMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.440000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.490000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                       srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.610000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                       srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.980000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 1.080000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30              srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30              srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.160000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.500000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 2.570000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                 srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 4.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                 srt:ProductOrServiceAxis:abbv:OtherEyeCareMember; abbv:KeyProductPortfolioAxis:abbv:EyeCareMember 5.140000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                   srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.840000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.670000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                   srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.260000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                   srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30          srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.910000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 2.020000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30          srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.550000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:abbv:MAVYRETMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 4.070000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                             srt:ProductOrServiceAxis:abbv:MAVYRETMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.750000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                             srt:ProductOrServiceAxis:abbv:MAVYRETMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.690000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                             srt:ProductOrServiceAxis:abbv:MAVYRETMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 6.810000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                             srt:ProductOrServiceAxis:abbv:MAVYRETMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 7.180000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                     srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 4.040000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                     srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.720000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                     srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 7.590000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                     srt:ProductOrServiceAxis:abbv:CreonMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 6.570000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30          srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 2.470000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 2.110000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30          srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 3.860000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30          srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:country:US; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 4.680000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30 srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.100000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30 srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30 srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 2.000000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30 srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; srt:StatementGeographicalAxis:us-gaap:NonUsMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 1.900000e+07
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                    srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 2.580000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                    srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 2.210000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                    srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 4.060000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                    srt:ProductOrServiceAxis:abbv:LinzessConstellaMember; abbv:KeyProductPortfolioAxis:abbv:OtherKeyProductsMember 4.870000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 6.030000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 8.100000e+08
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-30                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 1.350000e+09
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax 2024-06-30                                                                                                                 srt:ProductOrServiceAxis:abbv:OtherProductsMember 1.554000e+09
                                           us-gaap:Revenues 2025-06-30                                                                                                                                                                   1.542300e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                   1.446200e+10
                                           us-gaap:Revenues 2025-06-30                                                                                                                                                                   2.876600e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                   2.677200e+10
                                           us-gaap:Revenues 2025-06-30                                                                                                                                                                   1.542300e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                   1.446200e+10
                                           us-gaap:Revenues 2025-06-30                                                                                                                                                                   2.876600e+10
                                           us-gaap:Revenues 2024-06-30                                                                                                                                                                   2.677200e+10
                                us-gaap:OperatingIncomeLoss 2025-06-30                                                                                                                                                                   4.894000e+09
                                us-gaap:OperatingIncomeLoss 2024-06-30                                                                                                                                                                   3.998000e+09
                                us-gaap:OperatingIncomeLoss 2025-06-30                                                                                                                                                                   8.627000e+09
                                us-gaap:OperatingIncomeLoss 2024-06-30                                                                                                                                                                   6.796000e+09